Nivolumab-Induced Large-Duct Cholangiopathy Treated with Ursodeoxycholic Acid and Tocilizumab
Chanakyaram A. Reddy(Baylor University Medical Center), Andrew W. Tai(Women's and Children's Hospital), Bryan J. Schneider(Georgetown University), Lindsay M Brackett(University of Michigan)
Cited by 29
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2020|484
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|416